A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

• Status: RECRUITING
• Trial end date: 2029-11-01

Summary

The goal of this clinical study is to assess the efficacy of BNT323/DB-1303 compared with investigator's choice of chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the endometrial cancer population with prior immune checkpoint inhibitor (ICI) treatment.

• Phase: PHASE3

Details

• Lead Sponsor: BioNTech SE
• Collaborator: DualityBio Inc.
• Treatments: Doxorubicin; Paclitaxel